<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24579075</article-id><article-id pub-id-type="pmc">3918689</article-id><article-id pub-id-type="doi">10.1155/2014/208064</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Long-Term Use of Probiotics <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> Has a Prophylactic Effect on the Occurrence and Severity of Pouchitis: A Randomized Prospective Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tomasz</surname><given-names>Banasiewicz</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zoran</surname><given-names>Stojcev</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jaros&#x00142;aw</surname><given-names>Walkowiak</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ryszard</surname><given-names>Marciniak</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marcin</surname><given-names>Grochowalski</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Robert</surname><given-names>Burdy&#x00144;ski</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Piotr</surname><given-names>Krokowicz</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lukasz</surname><given-names>Krokowicz</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jacek</surname><given-names>Paszkowski</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Piotr</surname><given-names>Gronek</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Przemys&#x00142;aw</surname><given-names>Pyda</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Micha&#x00142;</surname><given-names>Drews</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznan University of Medical Sciences, Ulica Przybyszewskiego 49, 60-355 Pozna&#x00144;, Poland</aff><aff id="I2"><sup>2</sup>Regional Specialist Hospital, Department of General, Vascular and Oncologic Surgery, 76-200 Slupsk, Poland</aff><aff id="I3"><sup>3</sup>Department of Oncologic Surgery, Gdansk Medical University, 80-210 Gdansk, Poland</aff><aff id="I4"><sup>4</sup>I Chair of Pediatrics, Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, 60-572 Pozna&#x00144;, Poland</aff><aff id="I5"><sup>5</sup>Department of General and Colorectal Surgery, Poznan University of Medical Sciences, 61-285 Pozna&#x00144;, Poland</aff><aff id="I6"><sup>6</sup>Department of Physiology, University School of Physical Education, 61-871 Pozna&#x00144;, Poland</aff><author-notes><corresp id="cor1">*Banasiewicz Tomasz: <email>tbanasiewicz@op.pl</email></corresp><fn fn-type="other"><p>Academic Editor: Michael Mahler</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>21</day><month>1</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>208064</elocation-id><history><date date-type="received"><day>1</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Banasiewicz Tomasz et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Aim</italic>. The aim of the study was to assess the impact of the long-term use of the composite probiotics in patients after restorative proctocolectomy. <italic>Method</italic>. Forty-three patients (20 females and 23 males, aged 21 to 68 years) after restorative proctocolectomy were included in the study. After randomization patients were divided into placebo group and treatment group with oral intake of probiotic containing <italic>Lactobacillus acidophilus</italic>, <italic>Lactobacillus delbrueckii subsp. bulgaricus</italic>, and <italic>Bifidobacterium bifidus</italic>. Patients were investigated during initial visit and during final visit after 9 months. All patients were subjected to standard clinical and endoscopic examination with microscopic study of the specimens. Concentrations of calprotectin and pyruvate kinase isoenzyme M2-PK were determined in all cases. <italic>Results</italic>. The average severity of pouchitis and the number of patients with pouchitis significantly decrease after 9 months of the probiotic taking. The concentrations of calprotectin and pyruvate kinase isoenzyme M2-PK significantly decreased after the therapy. <italic>Conclusions</italic>. Nine months of the probiotic treatment (<italic>Lactobacillus acidophilus</italic>, <italic>Lactobacillus delbrueckii subsp. bulgaricus</italic>, and <italic>Bifidobacterium bifidus</italic>) reduced the number of patients with pouchitis, decreased the PDAI score, and also decreased the fecal pyruvate kinase and calprotectin. The long-term probiotics use is safe and well accepted and can be an effective method of the pouchitis prevention.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The Western human diet contains several thousand times less bacteria than preindustrialized diets, mainly due to improved hygiene and nutrition and the use of processed and sterile foods which contain artificial sweeteners and preservatives, rather than fresh fruits and vegetables [<xref rid="B1" ref-type="bibr">1</xref>]. Decreased concentration of the gut microbiome or dysbiosis may be implicated in gastrointestinal disorders including diarrheal diseases, ulcerative colitis, inflammatory bowel diseases, and life style diseases [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>The use of probiotics in the treatment of the different GI tract diseases seems to be still more popular. Pouchitis&#x02014;inflammation of the intestinal mucosa of the small intestine&#x02014;is a common complication of restorative proctocolectomy. The data suggest positive role of the probiotics, especially in prevention of recurrence [<xref rid="B3" ref-type="bibr">3</xref>]. The randomized controlled trials using probiotics in patients with different inflammatory bowel diseases are required for probiotics to become mainstream therapy [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>].</p><p>The aim of the study was to assess the impact of the long-term use of the composite probiotic (<italic>Lactobacillus acidophilus</italic>, <italic>Lactobacillus delbrueckii subsp. bulgaricus</italic>, and <italic>Bifidobacterium bifidus</italic>) in patients after restorative proctocolectomy.</p></sec><sec id="sec2"><title>2. Material and Methods</title><p>Forty-three patients (20 females and 23 males, aged 21 to 68 years) after restorative proctocolectomy, operated on for ulcerative colitis (UC) and familial adenomatous polyposis (FAP) and admitted to outpatient clinic according to prescheduled followup and without acute signs of the pouchitis or other GI tract severe disorders, were included in the study. Patients were investigated during initial visit and during final visit after 9 months. During the followup 3 patients withdrew from the study&#x02014;1 patient in placebo group and 2 in probiotic group. In all patients clinical, endoscopical, and histopathological examinations were done during both visits. Before the initial visit, during phone registration, patients were informed about stool samples collection day before or in the day of the visit. Samples taken more than 2 hours before the visit were stored in +4&#x000b0;C (refrigerator). The stool samples were also collected with the same rules before final visit. After investigation patients were randomized into two groups: placebo and probiotic groups. The study was performed in accordance with the Helsinki declaration and the regulations of the Ethics Committee of Poznan University of Medical Sciences.</p><sec id="sec2.1"><title>2.1. Pouchitis Disease Activity Index (PDAI)</title><p>Modified Pouch Disease Activity Index (PDAI) was determined in all IPAA patients, including clinical, endoscopic, and histopathological (Moskowitz criteria) parameters [<xref rid="B6" ref-type="bibr">6</xref>]. Pouchitis was recognized, if the total points were &#x02265;7.</p></sec><sec id="sec2.2"><title>2.2. Pyruvate Kinase and Calprotectin Level</title><p>Each participant (both patients and healthy controls) provided 3 samples of stool, which underwent spectrophotometric assessment of levels of calprotectin (Immundiagnostik AG, Bensheim, Germany) [<xref rid="B7" ref-type="bibr">7</xref>] and pyruvate kinase isoenzyme M2-PK (Schebo-Biotech, Giessen, Germany), after double reaction with monoclonal antibodies binding with specific epitopes of the enzymes (enzyme-linked immunosorbent assay, ELISA) [<xref rid="B8" ref-type="bibr">8</xref>]. Mean values from 3 measurements were calculated and used in further analyses.</p></sec><sec id="sec2.3"><title>2.3. Probiotic Therapy</title><p>The composite probiotic Trilac (Allergon AB, Angelholm, Sweden) was used in the investigation. Each capsule contained 0,6 &#x000d7; 10<sup>9</sup> lyophilized <italic>Lactobacillus acidophilus</italic>, 0,4 &#x000d7; 10<sup>9</sup> lyophilized <italic>Lactobacillus delbrueckii subsp. bulgaricus,</italic> and 0,6 &#x000d7; 10<sup>9</sup> lyophilized <italic>Bifidobacterium bifidus.</italic> Patients in the probiotic group took Trilac in the doses of 3 &#x000d7; 2 capsules daily during first month and 2 &#x000d7; 1 capsule during next months. Visual analogue placebo capsules were administered in the same dose.</p></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>Statistical analysis was performed using Statistica (Statsoft version 6.0). The statistical differences between groups were calculated using the Mann-Whitney test (nonpaired data).</p></sec></sec><sec id="sec3"><title>3. Results</title><p>During the treatment good tolerance of the used probiotic was observed. There were no side effects and complications in probiotic, as well as in placebo groups. All 3 patients, who did not finish the study (1 patient in placebo group and 2 in probiotic group) withdrew from the investigation due to noninvestigation related reasons (1 person accident, 2 persons emigration). The probiotic group (<italic>n</italic> = 19) and the control group (<italic>n</italic> = 21) did not differ significantly within age, time after surgery, number of patients with pouchitis, average PDAI, M2-PK level, and calprotectin level in the stool before the study.</p><p>After 9 months of the study the number of the patients with pouchitis, average PDAI, average M2-PK, and calprotectin level in the placebo group has not changed. In the probiotic group significantly lower numbers of the patients with pouchitis and lower average PDAI were observed, as well as the significant decreases of the M2-PK and calprotectin level in the stool. Average PDAI in probiotic treated group was 6.28 points before therapy and 4,43 points after therapy, with statistically important differences (<italic>P</italic> = 0.000342). The M2-PK average level was 92.3&#x02009;U/mL in probiotic group before therapy and 45.5&#x02009;U/mL after therapy, with statistically important differences (<italic>P</italic> = 0.000322). The same tendency was observed in the calprotectin level&#x02014;65.8&#x02009;mg/mL in probiotic group before therapy and 30.1&#x02009;mg/mL in the same group after therapy (<italic>P</italic> = 0.000236). Decrease of the average PDAI, the M2-PK, and calprotectin level means decreasing of the inflammation of the pouch mucosa.</p><p>Exact values reflecting the changes in the pouchitis frequency, PDAI, M2-PK, and calprotectin level before and after the study are presented in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec4"><title>4. Discussion</title><p>Probiotics are popular method of the treatment of different gastrointestinal pathologies, mostly inflammatory. The main indications are irritable bowel syndrome and pouchitis. Probiotics are prescribed or recommended much more by the gastroenterologist as by the surgeons [<xref rid="B9" ref-type="bibr">9</xref>]. Probiotics are an option for recurrent and relapsing antibiotic sensitive pouchitis; this suggests potential for benefit in select patients, but concerns remain about proof from trials [<xref rid="B10" ref-type="bibr">10</xref>].</p><p>Information about the effectiveness of such treatment is not clear. Given the limited number of lines of evidence of probiotics efficacy from controlled trials and the many unanswered questions on probiotic treatment, only prescribing probiotic treatment for mild inflammation of the intestinal mucosa and as prophylaxis of the inflammation is recommended [<xref rid="B11" ref-type="bibr">11</xref>]. The short-term probiotics therapy has limited effectiveness [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>In the probiotics treatment of pouchitis lasting for 2 months no significant differences of pouchitis process activity using PDAI scale were detected between probiotic and placebo intakes; however, significant decrease of bowel openings per day was observed in the probiotic group, as well as the subjective well-being improvement [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>The benefits of the probiotics therapy can be strain specific [<xref rid="B14" ref-type="bibr">14</xref>]. The very popular and commonly used probiotic is VSL number 3, whose effectiveness has been confirmed in clinical [<xref rid="B15" ref-type="bibr">15</xref>], experimental [<xref rid="B16" ref-type="bibr">16</xref>], and computer controlled [<xref rid="B17" ref-type="bibr">17</xref>] models. Another popular source of probiotics is probiotic containing yoghurt and drinks, very popular supplements recommended for patients among surgeons [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>In the presented study the composite probiotic Trilac, containing <italic>Lactobacillus acidophilus</italic>, <italic>Lactobacillus delbrueckii subsp. bulgaricus,</italic> and <italic>Bifidobacterium bifidus</italic> was used. There are a lot of studies that confirmed positive role of the probiotics <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> in gastrointestinal disorders and gut microbiota [<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>].</p><p>In our study the average severity of pouchitis measured with the PDAI score and the number of patients with pouchitis significantly decrease after 9 months of the probiotic taking. Also more objective parameters, as the fecal markers, confirmed the positive role of the probiotic in limitation of the inflammation in the intestinal pouch mucosa. High efficacy of the probiotic therapy especially in the pouchitis patients is consistent with the observations of other authors [<xref rid="B22" ref-type="bibr">22</xref>]. This therapy was very well accepted by the patients, no side effects were observed, and the tolerance of the probiotic was high. In our opinion this method of the prevention of the pouchitis is very important, because the treatment of pouchitis is still not well established and in some cases complicated.</p><p>The other finding of the study is the confirmation of the usefulness of the noninvasive fecal markers in diagnosis and monitoring of the pouchitis. The used pyruvate kinase isoenzyme M2-PK in the study was first described as the marker of the pouchitis by Walkowiak et al. [<xref rid="B8" ref-type="bibr">8</xref>] and confirmed in the next studies [<xref rid="B23" ref-type="bibr">23</xref>]. Also fecal calprotectin is accepted tool for the detection and definition of the severity of the pouchitis [<xref rid="B24" ref-type="bibr">24</xref>]. Fecal markers are commonly accepted and adjunctive tools in overall evaluation of patients with inflammatory disease, as pouchitis, to monitor disease activity and modification of the treatment. This noninvasive method is much more safe and accepted than endoscopy and can help guide management in a more cost-effective manner [<xref rid="B25" ref-type="bibr">25</xref>].</p><p>In presented study correlation between fecal M2 pyruvate kinase and calprotectin correlated significantly with the severity of the pouchitis described in the PDAI score, as well as with the number of patients with recognized pouchitis.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Nine months of the probiotic treatment (<italic>Lactobacillus acidophilus</italic>, <italic>Lactobacillus delbrueckii subsp. bulgaricus,</italic> and <italic>Bifidobacterium bifidus</italic>) reduced the number of patients with pouchitis, decreased the average PDAI score, and also decreased the fecal pyruvate kinase and calprotectin. The long-term probiotics use is safe and well accepted and can be an effective method of pouchitis prevention.</p></sec></body><back><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ML</given-names></name><name><surname>Romanuk</surname><given-names>TN</given-names></name></person-group><article-title>A meta-analysis of probiotic efficacy for gastrointestinal diseases</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>4</issue><pub-id pub-id-type="other">2-s2.0-84860003661</pub-id><pub-id pub-id-type="publisher-id">e34938</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Rashmi</surname><given-names>HM</given-names></name><name><surname>Srivastava</surname><given-names>AK</given-names></name><name><surname>Batish</surname><given-names>VK</given-names></name></person-group><article-title>Probiotics for human health -new innovations and emerging trends</article-title><source><italic>Gut Pathogens</italic></source><year>2012</year><volume>4</volume><issue>1, article 15</issue></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>GC</given-names></name><name><surname>Schirmer</surname><given-names>LL</given-names></name><name><surname>Anliker</surname><given-names>LE</given-names></name><name><surname>Tigges</surname><given-names>AE</given-names></name></person-group><article-title>Pharmacotherapy for acute pouchitis</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>2011</year><volume>45</volume><issue>9</issue><fpage>1127</fpage><lpage>1137</lpage><pub-id pub-id-type="other">2-s2.0-80052463855</pub-id><pub-id pub-id-type="pmid">21775695</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorak</surname><given-names>R</given-names></name><name><surname>Demeria</surname><given-names>D</given-names></name></person-group><article-title>Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease</article-title><source><italic>Gastroenterology Clinics of North America</italic></source><year>2012</year><volume>41</volume><issue>4</issue><fpage>821</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">23101689</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>BJ</given-names></name><name><surname>Dieleman</surname><given-names>LA</given-names></name></person-group><article-title>Probiotics in the treatment of human inflammatory bowel diseases: update 2011</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2011</year><volume>45</volume><issue>supplement 3</issue><fpage>S139</fpage><lpage>S144</lpage><pub-id pub-id-type="other">2-s2.0-80054108815</pub-id><pub-id pub-id-type="pmid">21992953</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuschen</surname><given-names>UA</given-names></name><name><surname>Autschbach</surname><given-names>F</given-names></name><name><surname>Allemeyer</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Long-term follow-up after ileoanal pouch procedure algorithm for diagnosis, classification, and management of pouchitis</article-title><source><italic>Diseases of the Colon and Rectum</italic></source><year>2001</year><volume>44</volume><issue>4</issue><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="other">2-s2.0-0035055766</pub-id><pub-id pub-id-type="pmid">11330575</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardt</surname><given-names>PD</given-names></name><name><surname>Mazurek</surname><given-names>S</given-names></name><name><surname>Toepler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer</article-title><source><italic>British Journal of Cancer</italic></source><year>2004</year><volume>91</volume><issue>5</issue><fpage>980</fpage><lpage>984</lpage><pub-id pub-id-type="other">2-s2.0-4644265292</pub-id><pub-id pub-id-type="pmid">15266315</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkowiak</surname><given-names>J</given-names></name><name><surname>Banasiewicz</surname><given-names>T</given-names></name><name><surname>Krokowicz</surname><given-names>P</given-names></name><name><surname>Hansdorfer-Korzon</surname><given-names>R</given-names></name><name><surname>Drews</surname><given-names>M</given-names></name><name><surname>Herzig</surname><given-names>K-H</given-names></name></person-group><article-title>Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis</article-title><source><italic>Scandinavian Journal of Gastroenterology</italic></source><year>2005</year><volume>40</volume><issue>12</issue><fpage>1493</fpage><lpage>1494</lpage><pub-id pub-id-type="other">2-s2.0-29744464361</pub-id><pub-id pub-id-type="pmid">16293562</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordina</surname><given-names>C</given-names></name><name><surname>Shaikh</surname><given-names>I</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Camilleri-Brennan</surname><given-names>J</given-names></name></person-group><article-title>Probiotics in the management of gastrointestinal disease: analysis of the attitudes and prescribing practices of gastroenterologists and surgeons</article-title><source><italic>Journal of Digestive Diseases</italic></source><year>2011</year><volume>12</volume><issue>6</issue><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="other">2-s2.0-82355169240</pub-id><pub-id pub-id-type="pmid">22118700</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>DR</given-names></name></person-group><article-title>Probiotics in inflammatory bowel diseases and associated conditions</article-title><source><italic>Nutrients</italic></source><year>2011</year><volume>3</volume><issue>2</issue><fpage>245</fpage><lpage>264</lpage><pub-id pub-id-type="other">2-s2.0-79952061363</pub-id><pub-id pub-id-type="pmid">22254095</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieleman</surname><given-names>L</given-names></name><name><surname>Hoentjen</surname><given-names>F</given-names></name></person-group><article-title>Probiotics have a limited role in the treatment of inflammatory bowel disease</article-title><source><italic>Nederlands Tijdschrift Voor Geneeskunde</italic></source><year>2012</year><volume>156</volume><issue>40</issue><pub-id pub-id-type="publisher-id">A5206</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>SD</given-names></name><name><surname>Culkin</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis</article-title><source><italic>Journal of Crohn'S and colitiS</italic></source><year>2013</year><volume>7</volume><issue>6</issue><fpage>460</fpage><lpage>466</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grochowalski</surname><given-names>M</given-names></name><name><surname>Banasiewicz</surname><given-names>T</given-names></name><name><surname>Marciniak</surname><given-names>R</given-names></name><etal/></person-group><article-title>Probiotics in the prophylaxis of pouchitis: preliminary report</article-title><source><italic>Proktologia</italic></source><year>2006</year><volume>7</volume><issue>1</issue><fpage>52</fpage><lpage>62</lpage><pub-id pub-id-type="other">2-s2.0-33846132942</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>K</given-names></name><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group><article-title>Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease</article-title><source><italic>Current Opinion in Gastroenterology</italic></source><year>2013</year><volume>29</volume><issue>2</issue><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">23286925</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrof</surname><given-names>EO</given-names></name></person-group><article-title>Probiotics and gastrointestinal disease: clinical evidence and basic science</article-title><source><italic>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</italic></source><year>2009</year><volume>8</volume><issue>3</issue><fpage>260</fpage><lpage>269</lpage><pub-id pub-id-type="other">2-s2.0-73549103855</pub-id><pub-id pub-id-type="pmid">20890386</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>CQ</given-names></name><name><surname>Meng</surname><given-names>FJ</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Sang</surname><given-names>LX</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name></person-group><article-title>VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-KappaB pathway in rat model of DSS-induced colitis</article-title><source><italic>Molecular and Cellular Biochemistry</italic></source><year>2013</year><volume>374</volume><issue>1-2</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">23271629</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>A</given-names></name><name><surname>Heinsen</surname><given-names>F-A</given-names></name><name><surname>Koenen</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine</article-title><source><italic>BMC Microbiology</italic></source><year>2012</year><volume>12, article 47</volume><pub-id pub-id-type="other">2-s2.0-84858837801</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodes</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of probiotics <italic>lactobacillus</italic> and <italic>bifidobacterium</italic> on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model</article-title><source><italic>Journal of Microbiology and Biotechnology</italic></source><year>2013</year><volume>23</volume><issue>4</issue><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">23568206</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turroni</surname><given-names>F</given-names></name><name><surname>Ventura</surname><given-names>M</given-names></name><name><surname>Butt&#x000f3;</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Molecular dialogue between the human gut microbiota and the host: a <italic>Lactobacillus</italic> and <italic>bifidobacterium</italic> perspective</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2013</year><volume>10.1007/s00018-013-1318-0</volume></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>B-S</given-names></name><name><surname>Wu</surname><given-names>J-J</given-names></name><name><surname>Lo</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Impact of supplement with <italic>Lactobacillus</italic>- and <italic>bifidobacterium</italic>-containing yogurt on triple therapy for Helicobacter pylori eradication</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2002</year><volume>16</volume><issue>9</issue><fpage>1669</fpage><lpage>1675</lpage><pub-id pub-id-type="other">2-s2.0-0036734930</pub-id><pub-id pub-id-type="pmid">12197847</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>F</given-names></name><name><surname>Einarsson</surname><given-names>K</given-names></name><name><surname>Lidbeck</surname><given-names>A</given-names></name><name><surname>Orrhage</surname><given-names>K</given-names></name><name><surname>Nord</surname><given-names>CE</given-names></name></person-group><article-title>Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment</article-title><source><italic>Scandinavian Journal of Infectious Diseases</italic></source><year>1991</year><volume>23</volume><issue>2</issue><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="other">2-s2.0-0025905402</pub-id><pub-id pub-id-type="pmid">1906634</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sans</surname><given-names>M</given-names></name></person-group><article-title>Probiotics for inflammatory bowel disease: a critical appraisal</article-title><source><italic>Digestive Diseases</italic></source><year>2010</year><volume>27</volume><issue>supplement 1</issue><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="other">2-s2.0-77950846694</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Maestranzi</surname><given-names>S</given-names></name><name><surname>Duffy</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation</article-title><source><italic>European Journal of Gastroenterology and Hepatology</italic></source><year>2009</year><volume>21</volume><issue>5</issue><fpage>544</fpage><lpage>550</lpage><pub-id pub-id-type="other">2-s2.0-67651180580</pub-id><pub-id pub-id-type="pmid">19300275</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Maestranzi</surname><given-names>S</given-names></name><name><surname>Duffy</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis</article-title><source><italic>European Journal of Gastroenterology and Hepatology</italic></source><year>2008</year><volume>20</volume><issue>3</issue><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="other">2-s2.0-39849108182</pub-id><pub-id pub-id-type="pmid">18301296</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>BP</given-names></name><name><surname>Kane</surname><given-names>S</given-names></name></person-group><article-title>Fecal markers: calprotectin and lactoferrin</article-title><source><italic>Gastroenterology Clinics of North America</italic></source><year>2012</year><volume>41</volume><issue>2</issue><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="other">2-s2.0-84859635560</pub-id><pub-id pub-id-type="pmid">22500530</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the investigated group, pouchitis disease activity index (PDAI), and level of the pyruvate kinase (M2-PK) and calprotectin in the placebo and treatment group. Observation time&#x02014;9 months, with asterisk (*) signing the data with statistically significant differences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Patients</th><th align="center" rowspan="1" colspan="1">Placebo group before treatment</th><th align="center" rowspan="1" colspan="1">Placebo group after treatment</th><th align="center" rowspan="1" colspan="1">Probiotic group before treatment</th><th align="center" rowspan="1" colspan="1">Probiotic group after treatment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of patients with pouchitis (PDAI &#x02265; 7&#x02009;pts)</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Age of patients (years)</td><td align="center" rowspan="1" colspan="1">41.2</td><td align="center" rowspan="1" colspan="1">41.5</td><td align="center" rowspan="1" colspan="1">38.6</td><td align="center" rowspan="1" colspan="1">38.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Time from operation (years)</td><td align="center" rowspan="1" colspan="1">9.2</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">PDAI</td><td align="center" rowspan="1" colspan="1">5.97</td><td align="center" rowspan="1" colspan="1">5.72</td><td align="center" rowspan="1" colspan="1">6.28*</td><td align="center" rowspan="1" colspan="1">4.43*</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.115861</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.000342</td></tr><tr><td align="left" rowspan="1" colspan="1">M2-PK (U/mL)</td><td align="center" rowspan="1" colspan="1">87.4</td><td align="center" rowspan="1" colspan="1">90.1</td><td align="center" rowspan="1" colspan="1">92.3*</td><td align="center" rowspan="1" colspan="1">45.5*</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.877654</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.000322</td></tr><tr><td align="left" rowspan="1" colspan="1">Calprotectin (mg/L)</td><td align="center" rowspan="1" colspan="1">57.5</td><td align="center" rowspan="1" colspan="1">55.8</td><td align="center" rowspan="1" colspan="1">65.8*</td><td align="center" rowspan="1" colspan="1">30.1*</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.107476</td><td align="center" colspan="2" rowspan="1">
<italic>P</italic> = 0.000236</td></tr></tbody></table></table-wrap></floats-group></article>